This article explores the presence of tryptamines classified as NPS among the substances delivered for analysis to a harm-reduction organization, to describe the substances found in the samples after analysis, and to compare analytical results of regulated vs. non-regulated tryptamines. It argues that there is a need for further research in order to prevent the potential health risks associated with their use.
ResearchTags
2C-B
2C-X
alcohol
alprazolam
amphetamine
anxiety
benzodiacepine
bipolar
buprenorphine
bupropion
cannabis
cocaine
depression
DMT
drug checking service
drug testing
ecstasy
fentanyl
GBL
GHB
heroin
isotretinoin
ketamine
lidocaine
LSD
MDMA
memory
mephedrone
methadone
methamphetamine
methylone
methylphenidate
morphine
mushroom
NBOME
NPS
opiates
opium
oxandrolone
oxycodone
schizophrenia
speed
steroids
testosterone
tramadol
Recent posts
- Recent Adware Attack on site 16 December, 2020
- Back in Business & Overhaul 4 June, 2020
- Drug Crypto Markets at CND63 27 March, 2020
- Update regarding COVID-19 23 March, 2020
- Delays with our HPLC analyses 13 February, 2020
- Changes to how/when we quantify some substances 12 January, 2020